Dr. med. Tobias Gaska
Veröffentlichungen Dr. med. Tobias Gaska
Koautor der folgenden internationalen Veröffentlichungen mit Peer-Review-Verfahren (Zeitraum seit 2018):
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study.
Hemasphere.
2023 Jul 5;7(7):e904. doi: 10.1097/HS9.0000000000000904. eCollection 2023
Jul.
PMID: 37427146 Free PMC article.
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Blood. 2023
Aug 3;142(5):446-459. doi: 10.1182/blood.2023019634.
PMID: 37172204 Clinical
Trial.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
N Engl J Med.
2023 May 11;388(19):1739-1754. doi: 10.1056/NEJMoa2213093.
PMID: 37163621 Clinical
Trial.
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised,
active-controlled, phase 3 trial.
Lancet
Haematol. 2022 Nov;9(11):e810-e821. doi: 10.1016/S2352-3026(22)00263-0.
PMID: 36328040 Clinical
Trial.
Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis.
Br J
Haematol. 2022 Jul;198(2):401-404. doi: 10.1111/bjh.18231. Epub 2022 May 11.
PMID: 35538912 No abstract
available.
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Blood. 2022
Jan 13;139(2):177-187. doi: 10.1182/blood.2021010845.
PMID: 34758069 Clinical
Trial.
Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia. American Journal of Hematology. 96. 10.1002/ajh.26363.
The CLL12 trial: Ibrutinib versus placebo in treatment-naïve, early stage chronic lymphocytic leukemia. Blood. 139. 10.1182/blood.2021010845.
Outcomes of Anti-PD1 Treatment for Relapsed/Refractory Hodgkin Lymphoma: A German Hodgkin Study Group (GHSG) Multi-Center Real-World Analysis. Blood. 138. 4533-4533. 10.1182/blood-2021-153200.
A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial. Blood. 138. 71-71. 10.1182/blood-2021-146161.
Afatinib as first-line treatment in patients with EGFR -mutated non-small cell lung cancer in routine clinical practice. Therapeutic Advances in Medical Oncology. 13. 175883592110123. 10.1177/17588359211012361.
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung Cancer. 152. 10.1016/j.lungcan.2020.10.012.
Efficacy of afatinib in the clinical practice: Final results of the GIDEON study in EGFR mutated non-small cell lung cancer (NSCLC) in Germany.. Journal of Clinical Oncology. 38. e21636-e21636. 10.1200/JCO.2020.38.15_suppl.e21636.
IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE-BLIND RANDOMIZED CLL12 TRIAL. Hematological Oncology. 37. 38-40. 10.1002/hon.7_2629.
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trial. Annals of Hematology. 98. 10.1007/s00277-018-3578-0.
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study. Leukemia. 32. 10.1038/s41375-018-0268-9.
1449PEfficacy of afatinib in the clinical practice: First results of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC in Germany. Annals of Oncology. 29. 10.1093/annonc/mdy292.071.
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. The Lancet Oncology. 19. 10.1016/S1470-2045(18)30618-1.
Four versus Two Years of Rituximab Maintenance (R-Maintenance) Following Bendamustine Plus Rituximab (B-R): Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN Study). Clinical Lymphoma Myeloma and Leukemia. 18. S101-S103. 10.1016/j.clml.2018.06.072.
Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial).. Journal of Clinical Oncology. 36. 7515-7515. 10.1200/JCO.2018.36.15_suppl.7515.
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial (J Clin Oncol 2018 Jul 10;36(20):2024-2034. doi: 10.1200/JCO.2017.76.8093. Epub 2018 May 11.)
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study (Leukemia volume 32, pages2558–2571(2018) Received: 16 May 2018 / Revised: 26 July 2018 / Accepted: 9 August 2018), doi: 10.1038/s41375-018-0268-9)
- Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial (2019 Apr;98(4):897-907. doi: 10.1007/s00277-018-3578-0. Epub 2019 Jan 4.)